H. Keir (Dundee (Angus), United Kingdom), M. Loebinger (London, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
The prevalence and impact of autoantibodies among people with bronchiectasis: a data analysis of the EMBARC registry
M. Shteinberg (Haifa, Israel), E. Polverino (Barcelona, Spain), P. Burgel (Paris, France), C. Haworth (Cambridge, United Kingdom), K. Dimakou (Athens, Greece), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), F. Blasi (Milan, Italy), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle, Germany), M. Vendrell (Girona, Spain), A. Shoemark (Dundee, United Kingdom), J. Altenburg (Amsterdam, Netherlands), W. Boersma (Alkmaar, Netherlands), R. Wilson (London, United Kingdom), J. Chalmers (Dundee, United Kingdom), S. Elborn (Belfast, United Kingdom), S. Aliberti (Milan, Italy), P. Goeminne (Sint Niklaas, Belgium)
|   |
Characterizing Neisseria spp. as novel respiratory pathobionts in bronchiectasis
M. Mac Aogáin (Singapore, Singapore), L. Liang (Shenzhen, China), T. Xu (Singapore, Singapore), T. Jaggi (Singapore, Singapore), L. Chan (Singapore, Singapore), H. Keir (Dundee, Scotland, United Kingdom), A. Dicker (Dundee, Scotland, United Kingdom), J. Qu (Shenzhen, China), Y. Liu (Shenzhen, China), H. Cheng (Singapore, Singapore), M. Koh (Singapore, Singapore), T. Ong (Singapore, Singapore), A. Hou (Singapore, Singapore), J. Abisheganaden (Singapore, Singapore), T. Low (Singapore, Singapore), B. Oliver (Sydney, NSW, Australia), N. Tan (Singapore, Singapore), M. Fang (Singapore, Singapore), J. Chalmers (Dundee, Scotland, United Kingdom), S. Chotirmall (Singapore, Singapore)
| |
International BEAT-PCD Consensus Statement for infection prevention and control in Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives
J. Marthin (Copenhagen, Denmark), J. Lucas (Southampton, United Kingdom), M. Boon (Leuven, Belgium), S. Crowley (Oslo, Norway), C. Casualta (Bern, Switzerland), D. Destouches (Paris, France), E. Eber (Graz, Austria), A. Escribano (Valencia, Spain), E. Haarman (Amsterdam, Netherlands), C. Hogg (London, United Kingdom), B. Maitre (Paris, France), G. Marsh (London, United Kingdom), V. Martinu (Prague, Czech Republic), A. Moreno-Galdó (Madrid, Spain), H. Mussaffi ( Tel-Aviv, Israel), H. Omran ( Muenster, Germany), P. Pohunek (Prague, Czech Republic), B. Rindlisbacher ( Steffisburg, Switzerland), P. Robinson ( Parkville, Australia), D. Snijders (Padova, Italy), P. Yiallouros (Nicosia, Cyprus), W. Walker (Southampton, United Kingdom), H. Krogh Johansen (Copenhagen, Denmark), K. Nielsen (Copenhagen, Denmark)
| |
Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis
A. Shoemark (Dundee, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle, United Kingdom), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), W. Boersma (Alkmaar, Netherlands), C. Haworth (Cambridge, United Kingdom), M. Murris (Tolouse, France), K. Dimakou (Athens, Greece), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menéndez (Valencia, Spain), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), S. Elborn (Belfast, United Kingdom), S. Aliberti (Milan, Italy), J. Chalmers (Dundee, United Kingdom)
| |
Home Intravenous Antibiotic Therapy (HIVAT) for adult bronchiectasis patients: safe, efficacious and cost-effective
H. Chen (Middlesbrough, United Kingdom), H. Simmons (Middlesbrough, United Kingdom), V. Bradshaw (Middlesbrough, United Kingdom), S. Kalam (Middlesbrough, United Kingdom), E. Kane (Middlesbrough, United Kingdom), G. Antunes (Middlesbrough, United Kingdom)
| |
Acute exacerbation of bronchiectasis – Experience of a Tunisian pulmonology department
H. Mrassi (Tunis, Tunisia), I. Bachouch (Tunis, Tunisia), N. Khezami (Tunis, Tunisia), N. Belloumi (Tunis, Tunisia), F. Chermiti (Tunis, Tunisia), S. Fenniche (Tunis, Tunisia)
| |
Features of post-tuberculosis bronchiectasis: Tunisian comparative study
H. Mrassi (Tunis, Tunisia), I. Bachouch (Tunis, Tunisia), N. Khezami (Tunis, Tunisia), N. Belloumi (Tunis, Tunisia), F. Chermiti (Tunis, Tunisia), S. Fenniche (Tunis, Tunisia)
| |
O'Donnell Criteria as a Score of Bad Prognosis in Hospitalized Patients with Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis, an Observetional Study
F. ALHAMED ALDUIHI (Aleppo), A. Khoury (Aleppo)
| |
Diagnostic value of the Biofire® Filmarray Pneumonia panel compared to conventional sputum culture in patients with an exacerbation of bronchiectasis
P. Oscanoa Huaman (Barcelona, Spain), V. Alcaraz Serrano (Barcelona, Spain), R. Amaro Rodriguez (Barcelona, Spain), L. Bueno Freire (Barcelona, Spain), N. Vàzquez (Barcelona, Spain), L. Fernández-Barat (Barcelona, Spain), A. Torres Martí (Barcelona, Spain), V. Alcaraz Serrano (Barcelona, Spain)
| |
Long –term survival after a first hospitalization for bronchiectasis exacerbation
B. Urrutia Royo (Barcelona, Spain), I. García-Olivé (Barcelona, Spain), M. Compte Vives (Barcelona, Spain), C. Folgado López (Barcelona, Spain), A. Rosell (Barcelona, Spain), J. Abad Capa (Barcelona, Spain)
| |
Assessment of quality of life in patients with bronchiectasis
H. BAILI (MAHDIA, Tunisia), I. Touil (MAHDIA, Tunisia), M. Bali (MAHDIA, Tunisia), S. Bouchareb (MAHDIA, Tunisia), N. Keskes Boudawara (MAHDIA, Tunisia), Y. Brahem (MAHDIA, Tunisia), S. Ksissa (MAHDIA, Tunisia), J. Ayeb (MAHDIA, Tunisia), K. Jalel (MAHDIA, Tunisia), L. Boussofara (MAHDIA, Tunisia)
| |
Assessment of anxiety-depression disorders in patients with bronchiectasis
I. Touil (MAHDIA, Tunisia), H. BAILI (MAHDIA, Tunisia), M. Bali (MAHDIA, Tunisia), S. Bouchareb (MAHDIA, Tunisia), N. Keskes Boudawara (MAHDIA, Tunisia), Y. Brahem (MAHDIA, Tunisia), J. Ayeb (MAHDIA, Tunisia), S. Ksissa (MAHDIA, Tunisia), K. Jalel (MAHDIA, Tunisia), L. Boussofara (MAHDIA, Tunisia)
| |
Bronchiectasis surgery: indications and risk factors?
Z. Chaari (Sfax, Tunisia), A. Ammar (Sfax, Tunisia), W. Abid (Sfax, Tunisia), A. Hentati (Sfax, Tunisia), I. Frikha (Sfax, Tunisia)
| |
Small-airway dysfunction among non-cystic bronchiectasis patients with different Bronchiectasis Severity Index
C. Tan (Zhuhai, China), D. Ma (Zhuhai, China), C. Tu (Zhuhai, China), M. Chen (Zhuhai, China), K. Wang (Zhuhai, China), X. Zheng (Zhuhai, China), Y. Huang (Zhuhai, China), Z. Wang (Zhuhai, China), J. Wu (Zhuhai, China), J. Huang (Zhuhai, China), J. Liu (Zhuhai, China)
| |
Systematic review of lung clearance index (LCI) in non-cystic fibrosis (CF), non-primary ciliary dyskinesia (PCD) bronchiectasis (Bx)
C. Hine (Birmingham, United Kingdom), M. Desai (Birmingham, United Kingdom), J. Davies (London, United Kingdom), E. Sapey (Birmingham, United Kingdom), P. Nagakumar (Birmingham, United Kingdom)
| |
SYSTEMIC INFLAMMATION IN PATIENTS WITH STABLE NON-CYSTIC FIBROSIS BRONCHIECTASIS
L. Qin (Barcelona, Spain), M. Guitart (Barcelona, Spain), M. Alvarado-Miranda (Barcelona, Spain), X. Wang (Barcelona, Spain), E. Barreiro (Barcelona, Spain)
| |
LOSS OF MUSCLE MASS AND FUNCTION AND NUTRITIONAL ABNORMALITIES IN PATIENTS WITH BRONCHIECTASIS
X. Wang (Barcelona, Spain), A. Balaña-Corberó (Barcelona, Spain), J. Martínez-Llorens (Barcelona, Spain), M. Alvarado-Miranda (Barcelona, Spain), L. Qin (Barcelona, Spain), J. Tang (Barcelona, Spain), M. Admetlló (Barcelona, Spain), E. Hernández-Leal (Barcelona, Spain), A. Sancho-Muñoz (Barcelona, Spain), X. Duran (Barcelona, Spain), E. Barreiro (Barcelona, Spain)
| |
Pulmonary arterial enlargement is a predictor of higher risk of exacerbations in non-cystic fibrosis bronchiectasis patients
L. De Freitas (São Paulo, Brazil), B. Nunes (São Paulo, Brazil), R. Miranda (São Paulo, Brazil), A. Maia (São Paulo, Brazil), S. Rached (São Paulo, Brazil), A. Cukier (São Paulo, Brazil), R. Stelmach (São Paulo, Brazil), R. Carvalho Pinto (São Paulo, Brazil), R. Athanazio (São Paulo, Brazil)
| |
Predictive factors of bronchiectasis acute exacerbation severity
A. Ben Saad (Monastir, Tunisia), R. Kaddoussi (Monastir, Tunisia), A. Migaou (Monastir, Tunisia), N. Fahem (Monastir, Tunisia), S. Joobeur (Monastir, Tunisia), S. Cheikh Mhamed (Monastir, Tunisia), N. Rouatbi (Monastir, Tunisia)
| |